TRAW•benzinga•
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results
Summary
Traws Pharma (NASDAQ: TRAW) shares soar as company reports positive results for single-dose treatment of H5N1 bird flu. No adverse events reported.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga